Abstract | OBJECTIVE: PATIENTS AND METHODS: RESULTS: All of the patients had improvements in clinical manifestations after the first infusion of infliximab. At week 22, 18 of 21 (85.7%) patients were categorized as being in remission, 3 of 21 (14.3%) patients were categorized as having clinical improvement, and none of the patients were categorized as having no response. There was a statistically significant difference in all of the IBD activity indices at weeks 2, 6, 14, and 22 compared with time 0. The corticosteroid use was completely discontinued in 6 of 15 patients by week 22. CONCLUSIONS:
|
Authors | Juliana Tiemi, Saito Komati, Vera Lucia Sdepanian |
Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
Vol. 50
Issue 6
Pg. 628-33
(Jun 2010)
ISSN: 1536-4801 [Electronic] United States |
PMID | 20386321
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Infliximab
|
Topics |
- Adolescent
- Adrenal Cortex Hormones
(therapeutic use)
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Brazil
- Child
- Colitis, Ulcerative
(drug therapy)
- Crohn Disease
(drug therapy)
- Female
- Humans
- Infant
- Infliximab
- Male
- Remission Induction
- Severity of Illness Index
- Young Adult
|